Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Cancer Incidences - Current and Future Projection

4. Cancer Market Outlook: Current and Future
     4.1 Cancer Generics: Market Size

5. Market Drivers and Trends
     5.1 US Facing Cancer Generics Shortage
     5.2 Oncology Therapeutics: Major Focus Area
     5.3 Strategic Activity and Alliances on the Rise
     5.4 Companies Thriving for New Generic Cancer Drugs

6. Cancer Generic Drugs: Market Segmentation by Disease Types
     6.1 Lung Cancer
            6.1.1 Current and Future Incidence
            6.1.2 Regional Analysis
            6.1.3 Commercialized Drugs: Branded and Generics
     6.2 Breast Cancer
            6.2.1 Current and Future Incidence
            6.2.2 Regional Analysis
            6.2.3 Commercialized Drugs: Branded and Generics
     6.3 Colorectal Cancer
            6.3.1 Current and Future Incidence
            6.3.2 Regional Analysis
            6.3.3 Commercialized Drugs: Branded and Generics
     6.4 Stomach Cancer
            6.4.1 Current and Future Incidence
            6.4.2 Regional Analysis
            6.4.3 Commercialized Drugs: Branded and Generics
     6.5 Prostate Cancer
            6.5.1 Current and Future Incidence
            6.5.2 Regional Analysis
            6.5.3 Commercialized Drugs: Branded and Generics

7. Cancer Generic Drugs: Market Segmentation by Oral and Injectables
     7.1 Oral Generic Drugs
            7.1.1 Arimidex (Anastrozole)
            7.1.2 Casodex (Bicalutamide)
            7.1.3 Aromasin (Exemestane)
            7.1.4 Femara (Letrozole)
            7.1.5 Megace (Megestrol Acetate)
            7.1.6 Purinethol (Mercaptopurine)
            7.1.7 Tarceva (Erlotinib)
            7.1.8 Nolvadex (Tamoxifen Citrate)
            7.1.9 Eulexin (Flutamide)
            7.1.10 Hydrea (Hydroxyurea)
     7.2 Generic Injectables
            7.2.1 Camptosar (Irinotecan Hydrochloride)
            7.2.2 Velcade (Bortezomib)
            7.2.3 Taxotere (Docetaxel)
            7.2.4 Gemzar (Gemcitabine Hydrochloride)

8. Key Players
     8.1 Accord Healthcare
     8.2 Hospira
     8.3 Mylan
     8.4 Sun Pharmaceuticals
     8.5 Teva